

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3040982

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TAKAAKI MASUDA	09/08/2014
YOSHIYUKI MIYATA	09/11/2014
HIDEO KANEDA	09/05/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	POLA PHARMA INC.
<b>Street Address:</b>	8-9-5, NISHIGOTANDA
<b>Internal Address:</b>	SHINAGAWA-KU
<b>City:</b>	TOKYO
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	141-0031
<b>Name:</b>	NIHON NOHYAKU CO., LTD.
<b>Street Address:</b>	19-8, KYOBASHI 1-CHOME
<b>Internal Address:</b>	CHUO-KU
<b>City:</b>	TOKYO
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	104-8386
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14388218
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(949)760-9502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9497600404
<b>Email:</b>	efiling@knobbe.com
<b>Correspondent Name:</b>	KNOBBE, MARTENS, OLSON & BEAR LLP
<b>Address Line 1:</b>	2040 MAIN STREET
<b>Address Line 2:</b>	14TH FLOOR
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92614
<b>ATTORNEY DOCKET NUMBER:</b>	TOYA173.018APC

PATENT

<b>NAME OF SUBMITTER:</b>	CHE SWYDEN CHERESKIN, PH.D.
<b>SIGNATURE:</b>	/Che S. Chereskin/
<b>DATE SIGNED:</b>	09/26/2014
<b>Total Attachments: 4</b> source=TOYA173-018APC_Assignment#page1.tif source=TOYA173-018APC_Assignment#page2.tif source=TOYA173-018APC_Assignment#page3.tif source=TOYA173-018APC_Assignment#page4.tif	

**COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))**

*Application Data Sheet filed previously or concurrently*

Docket No.:

Page 1 of 4

Title: CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

Inventors: Takaaki MASUDA, Yoshiyuki MIYATA and Hideo KANEDA

***Declaration***

This Declaration is directed to the application identified above that:

Was filed on **June 24, 2013** as U.S. or International Application No. **PCT/JP2013/067952** and incorporating any amendments made thereto prior to the signature date of this Declaration.

As a named inventor, I declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

***Assignment from Inventors***

WHEREAS, **above-identified inventors** (individual(s) hereinafter "ASSIGNOR") invented certain new and useful improvements, technology, inventions, developments, ideas, ornamental designs, or discoveries, and hereby assign or are under an obligation to assign to the below identified Assignee the above-titled application (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States (identified above) has been prepared for filing with the United States Patent and Trademark Office (hereinafter the "Application").

AND WHEREAS, **POLA PHARMA INC.**, with its principal place of business at 8-9-5, Nishigotanda, Shinagawa-ku, Tokyo 141-0031 Japan and **NIHON NOHYAKU CO., LTD.**, with its principal place of business at 19-8, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8386 Japan (hereinafter the "ASSIGNEE"), desires to acquire the entire right, title, and interest in and to the Application and the Work.

NOW, THEREFORE, for good and valuable consideration of which receipt is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title, and interest throughout the world in the Application and the Work, including all patent properties filed or issued upon the Application and the Work; where "Patent Properties" include, but are not limited to:

all provisional applications relating thereto (including but not limited to U.S. Provisional Application No(s)., filed );

all nonprovisional applications claiming priority to aforementioned provisional(s) and/or the present Application, including, all divisions, continuations, continuations-in-part, and reissues, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof; and

**COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))**

*Application Data Sheet filed previously or concurrently*

Docket No.:

Page 2 of 4

Title: CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL  
COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

Inventors: Takaaki MASUDA, Yoshiyuki MIYATA and Hideo KANEDA

all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals and reissues thereof.

ASSIGNOR hereby acknowledges the ASSIGNEE as the Applicant for all aforementioned patent properties, and authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting the Work, and testify in any legal proceeding, assist in the preparation of any other Patent Property relating to the Application and the Work or any improvements made thereto, sign/execute all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the Work in all countries.

Legal Name of inventor: Takaaki MASUDA

Signature: Takaaki Masuda Date: 2014.9.8

Witnessed by: Makoto Kimura

Witness Name (printed): Makoto Kimura

**COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))**

*Application Data Sheet filed previously or concurrently*

Docket No.:

Page 3 of 4

Title: CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL  
COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

Inventors: Takaaki MASUDA, Yoshiyuki MIYATA and Hideo KANEDA

Legal Name of inventor: Yoshiyuki MIYATA

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

11, 09, 2014

Witnessed by: \_\_\_\_\_

Makoto Kimura

Witness Name (printed): \_\_\_\_\_

Makoto Kimura

**COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))**

*Application Data Sheet filed previously or concurrently*

Docket No.:

Page 4 of 4

Title: CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL  
COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

Inventors: Takaaki MASUDA, Yoshiyuki MIYATA and Hideo KANEDA

Legal Name of inventor: Hideo KANEDA

Signature: Hideo Kaneda Date: Sep. 5, 2014

Witnessed by: Hideo Takaishi

Witness Name (printed): Hideo Takaishi